Press Releases

InVivo Therapeutics Appoints Richard Toselli, M.D. as Chief Medical Officer

Published: July 10, 2017

CAMBRIDGE, Mass. (July 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the appointment of Richard Toselli, M.D., as Chief Medical Officer, effective July 5, 2017. Dr. Toselli, a fellowship-trained spinal neurosurgeon, will assume all responsibilities related to the company’s clinical and regulatory strategy. Prior to joining InVivo, Dr. Toselli served as Chief Medical Officer for Cochlear Limited. In that role, he was responsible for global clinical, regulatory, and medical affairs teams reporting to the CEO. Prior to that, Dr. Toselli served five years at Sanofi in various levels of increasing responsibility, including Vice President of Global Medical Affairs – […]

View Article
InVivo Therapeutics Announces UCHealth Memorial Hospital as New Site for INSPIRE Study

Published: June 29, 2017

CAMBRIDGE, Mass. (June 29, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the UCHealth Memorial Hospital in Colorado Springs, CO has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury.  Thomas Schroeppel, M.D., has been named Principal Investigator at the site. “I am thrilled to bring The INSPIRE Study and this innovative technology to the UCHealth Memorial Hospital, especially to help those who suffer from the devastating condition of spinal cord injury,” Dr. Schroeppel […]

View Article
InVivo Therapeutics Announces Positive Motor Recovery Assessments in Two Patients in the INSPIRE Study of the Neuro-Spinal Scaffold™

Published: June 28, 2017

– Continued Improvement from AIS B to AIS C for Two Patients with Early Conversions – CAMBRIDGE, Mass. (June 28, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that two patients in the INSPIRE study of the Neuro-Spinal Scaffold have improved from sensory incomplete AIS B spinal cord injury (SCI) to motor incomplete AIS C SCI in their most recent INSPIRE assessments. These are the second and third patients in the INSPIRE study to have reached AIS C motor incomplete classification. One of these patients was enrolled in May 2016 and converted from complete AIS A SCI to incomplete AIS […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Thomas Jefferson University Hospital

Published: June 27, 2017

CAMBRIDGE, Mass. (June 27, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Thomas Jefferson University Hospital in Philadelphia, PA. James Harrop, M.D., Professor of Neurological and Orthopedic Surgery, Co-Director at the Delaware Valley Spinal Cord Injury Center, and Principal Investigator at the site, and Josh Heller, M.D., successfully performed the surgery and implantation approximately 22 hours after the injury occurred.   Dr. Harrop […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Allegheny General Hospital

Published: June 20, 2017

CAMBRIDGE, Mass. (June 20, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Allegheny General Hospital in Pittsburgh, PA, part of the Allegheny Health Network (AHN). Drs. Dan Altman, Nestor Tomycz, and Terrence Julien successfully performed the surgery and implantation approximately 21 hours after the injury occurred. Dr. Julien, System Co-Director of Minimally Invasive Spine Surgery and Principal Investigator, said, “We are all hoping […]

View Article
InVivo Therapeutics to Present at JMP Securities Annual Life Sciences Conference

Published: June 12, 2017

–   Updated Presentation Time Announced – CAMBRIDGE, Mass. (June 15, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the JMP Securities Annual Life Sciences Conference on Tuesday, June 20, 2017 at 2:30 PM ET at the St. Regis New York in New York City. This is the first time that the company has been invited to present at the JMP Securities Annual Life Sciences Conference.  The conference will include company executives, KOLs, physicians, patients and industry experts discussing a variety of healthcare topics. Mr. Perrin’s presentation will highlight […]

View Article
InVivo Therapeutics Announces Posting of Management Presentation Recording from Annual Shareholders Meeting

Published: June 1, 2017

CAMBRIDGE, Mass. (June 1, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced the posting of the management presentation and Q&A session recording from the 2017 Annual Shareholders Meeting held on May 30th, 2017. The recording is available on the investor relations page of InVivo’s website at https://www.invivotherapeutics.com/investor-relations/annual-meeting/. Mark Perrin, Chief Executive Officer and Chairman, said, “I was pleased with the turnout at this year’s annual shareholders meeting. The meeting was a great opportunity for me to answer questions directly from our shareholders while providing some key updates on our recent progress.  I look forward to continued opportunities to communicate with […]

View Article
InVivo Therapeutics Announces Update to the Contemporary Thoracic SCI Registry Study (the “CONTEMPO Registry Study”)

Published: May 30, 2017

– Study to Include Reeve Foundation North American Clinical Trials Network (NACTN) Registry – CAMBRIDGE, Mass. (May 30, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that data from the Christopher & Dana Reeve Foundation NACTN Registry will be included in the Contemporary Thoracic SCI Registry Study (now called the “CONTEMPO Registry Study”), a complement to the ongoing INSPIRE study of the Neuro-Spinal Scaffold™. The CONTEMPO Registry Study is intended to provide comprehensive natural history benchmarks for INSPIRE study results that include spinal cord injury (SCI) patients with similar baseline characteristics treated since 2006. The NACTN registry is derived from […]

View Article
InVivo Therapeutics Announces Presentation at Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting

Published: May 9, 2017

CAMBRIDGE, Mass. (May 9, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Kristin Neff, Vice President, Clinical Operations, will present at the Combined Canadian Spinal Cord and Ontario Spinal Cord Injury Research Network Meeting on Saturday, May 13, 2017 at 2:40 PM ET at the Marriott Eaton Center in Toronto, Ontario. Ms. Neff will present an abstract titled “Interim Clinical Results from the Ongoing INSPIRE Pivotal Study to Assess the Safety and Probable Benefit of the Investigational Neuro-Spinal Scaffold for Treatment of Acute Thoracic AIS A Spinal Cord Injury.” Mark Perrin, Chairman and CEO, said, “The Canadian Spinal Cord […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study at Oregon Health and Science University

Published: May 8, 2017

CAMBRIDGE, Mass. (May 8, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into The INSPIRE Study  (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at Oregon Health & Science University (OHSU) in Portland, Oregon. Jason J. Chang, M.D., Assistant Professor of Neurological Surgery and co-study investigator, performed the surgery and implantation approximately 77 hours after the injury occurred. Mark Perrin, InVivo’s Chief Executive Officer and Chairman, said, “We were pleased to hear that the procedure was a […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.